| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medical Oncology | 33 | 2022 | 2321 | 3.350 |
Why?
|
| Neoplasms | 107 | 2022 | 22173 | 2.700 |
Why?
|
| Antineoplastic Agents | 95 | 2017 | 13642 | 2.020 |
Why?
|
| Drug Approval | 9 | 2017 | 814 | 1.860 |
Why?
|
| Methotrexate | 80 | 1999 | 1719 | 1.440 |
Why?
|
| Ethics, Research | 3 | 2018 | 176 | 1.080 |
Why?
|
| Drug Discovery | 4 | 2016 | 1051 | 1.050 |
Why?
|
| Clinical Trials as Topic | 36 | 2022 | 8002 | 0.950 |
Why?
|
| Publishing | 5 | 2013 | 833 | 0.890 |
Why?
|
| Clinical Trials, Phase I as Topic | 6 | 2014 | 326 | 0.860 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2016 | 297 | 0.840 |
Why?
|
| United States Food and Drug Administration | 11 | 2016 | 1664 | 0.840 |
Why?
|
| Publications | 2 | 2019 | 194 | 0.830 |
Why?
|
| Neuregulin-1 | 2 | 2013 | 135 | 0.800 |
Why?
|
| Periodicals as Topic | 8 | 2013 | 1463 | 0.740 |
Why?
|
| Drug Industry | 6 | 2011 | 788 | 0.710 |
Why?
|
| Dimethylnitrosamine | 1 | 2020 | 17 | 0.710 |
Why?
|
| Drug Design | 9 | 2015 | 1048 | 0.710 |
Why?
|
| Conflict of Interest | 2 | 2018 | 554 | 0.650 |
Why?
|
| Humans | 383 | 2023 | 761596 | 0.620 |
Why?
|
| Lymphoma | 35 | 2020 | 1901 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 32 | 2023 | 11742 | 0.610 |
Why?
|
| Pharmacogenetics | 4 | 2017 | 675 | 0.590 |
Why?
|
| Molecular Targeted Therapy | 5 | 2016 | 2811 | 0.570 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 426 | 0.520 |
Why?
|
| Polyglutamic Acid | 12 | 1993 | 47 | 0.500 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2015 | 94 | 0.500 |
Why?
|
| Giant Cell Tumors | 1 | 2015 | 89 | 0.500 |
Why?
|
| Drug Resistance | 35 | 1994 | 1596 | 0.490 |
Why?
|
| Antimetabolites, Antineoplastic | 12 | 1999 | 646 | 0.490 |
Why?
|
| Deoxycytosine Nucleotides | 2 | 2014 | 14 | 0.480 |
Why?
|
| Lymphoma, Non-Hodgkin | 20 | 2021 | 1374 | 0.480 |
Why?
|
| Breast Neoplasms | 37 | 2021 | 21019 | 0.480 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2007 | 629 | 0.470 |
Why?
|
| Mental Recall | 1 | 2021 | 1221 | 0.470 |
Why?
|
| Immunotherapy | 4 | 2023 | 4652 | 0.470 |
Why?
|
| Deoxycytidine Kinase | 1 | 2014 | 11 | 0.470 |
Why?
|
| Drug Evaluation | 15 | 2004 | 641 | 0.470 |
Why?
|
| Attitude to Health | 2 | 2021 | 2025 | 0.460 |
Why?
|
| Folic Acid Antagonists | 23 | 1991 | 75 | 0.460 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 122 | 0.440 |
Why?
|
| Pyridazines | 1 | 2015 | 202 | 0.440 |
Why?
|
| Physician-Patient Relations | 16 | 2011 | 3251 | 0.440 |
Why?
|
| Peer Review, Research | 2 | 2015 | 340 | 0.440 |
Why?
|
| Lung Neoplasms | 19 | 2018 | 13381 | 0.440 |
Why?
|
| Biosynthetic Pathways | 1 | 2014 | 136 | 0.430 |
Why?
|
| Receptor, erbB-2 | 3 | 2013 | 2557 | 0.420 |
Why?
|
| Fluorouracil | 34 | 2004 | 1642 | 0.420 |
Why?
|
| Genes, ras | 1 | 2015 | 654 | 0.420 |
Why?
|
| Carcinoma, Small Cell | 4 | 2008 | 420 | 0.410 |
Why?
|
| Drugs, Investigational | 2 | 2011 | 212 | 0.410 |
Why?
|
| Colposcopy | 1 | 2013 | 150 | 0.400 |
Why?
|
| Leadership | 2 | 2021 | 1385 | 0.400 |
Why?
|
| Attitude to Death | 4 | 2011 | 400 | 0.400 |
Why?
|
| Sulfones | 2 | 2014 | 448 | 0.400 |
Why?
|
| Pyrroles | 2 | 2015 | 1125 | 0.380 |
Why?
|
| Aminopyridines | 1 | 2015 | 573 | 0.380 |
Why?
|
| Plagiarism | 1 | 2011 | 22 | 0.370 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 20 | 2023 | 1405 | 0.350 |
Why?
|
| Vinca Alkaloids | 6 | 1994 | 36 | 0.350 |
Why?
|
| Drug Resistance, Multiple | 8 | 2009 | 255 | 0.350 |
Why?
|
| ras Proteins | 1 | 2015 | 1054 | 0.350 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 18 | 1993 | 133 | 0.340 |
Why?
|
| Authorship | 2 | 2011 | 284 | 0.330 |
Why?
|
| Imidazoles | 1 | 2015 | 1180 | 0.320 |
Why?
|
| History, 20th Century | 8 | 2016 | 2767 | 0.320 |
Why?
|
| History, 21st Century | 6 | 2016 | 1567 | 0.320 |
Why?
|
| Pyrimidines | 6 | 2014 | 3028 | 0.310 |
Why?
|
| Patient-Centered Care | 5 | 2022 | 1421 | 0.310 |
Why?
|
| Acquired Immunodeficiency Syndrome | 6 | 2014 | 2199 | 0.310 |
Why?
|
| Multilingualism | 1 | 2009 | 87 | 0.310 |
Why?
|
| Paclitaxel | 10 | 1999 | 1732 | 0.300 |
Why?
|
| Radiation Oncology | 2 | 2015 | 563 | 0.300 |
Why?
|
| Translating | 1 | 2009 | 143 | 0.300 |
Why?
|
| Mutation | 8 | 2021 | 30053 | 0.300 |
Why?
|
| Verapamil | 5 | 1999 | 242 | 0.300 |
Why?
|
| Quinazolines | 12 | 2004 | 1371 | 0.300 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2011 | 495 | 0.290 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1745 | 0.290 |
Why?
|
| Thymidylate Synthase | 15 | 2004 | 74 | 0.290 |
Why?
|
| United States | 38 | 2022 | 72340 | 0.280 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2008 | 161 | 0.280 |
Why?
|
| National Institutes of Health (U.S.) | 10 | 1995 | 793 | 0.280 |
Why?
|
| Doxorubicin | 25 | 2023 | 2224 | 0.270 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2015 | 1159 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 2828 | 0.270 |
Why?
|
| Ethics, Medical | 4 | 2008 | 783 | 0.270 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2016 | 2020 | 0.270 |
Why?
|
| Drugs, Generic | 1 | 2011 | 448 | 0.270 |
Why?
|
| Vincristine | 29 | 2023 | 1036 | 0.260 |
Why?
|
| Biomedical Research | 2 | 2014 | 3429 | 0.260 |
Why?
|
| Communication Barriers | 1 | 2009 | 414 | 0.260 |
Why?
|
| Smoking | 2 | 2021 | 9053 | 0.260 |
Why?
|
| Cyclophosphamide | 34 | 2023 | 2220 | 0.260 |
Why?
|
| Communication | 8 | 2008 | 3875 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2013 | 5305 | 0.260 |
Why?
|
| Device Approval | 1 | 2007 | 163 | 0.250 |
Why?
|
| Cancer Care Facilities | 4 | 2015 | 422 | 0.250 |
Why?
|
| Molecular Biology | 1 | 2009 | 576 | 0.250 |
Why?
|
| Physicians | 2 | 2022 | 4591 | 0.250 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1551 | 0.240 |
Why?
|
| Patient Care | 1 | 2010 | 622 | 0.240 |
Why?
|
| Health Education | 2 | 2009 | 1052 | 0.240 |
Why?
|
| Terrorism | 1 | 2007 | 211 | 0.240 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 774 | 0.230 |
Why?
|
| Cytarabine | 22 | 1999 | 698 | 0.230 |
Why?
|
| Prejudice | 1 | 2008 | 570 | 0.230 |
Why?
|
| Research Design | 6 | 2007 | 6180 | 0.230 |
Why?
|
| Awards and Prizes | 1 | 2008 | 360 | 0.230 |
Why?
|
| Trust | 2 | 2006 | 530 | 0.230 |
Why?
|
| Neoplasm Metastasis | 13 | 2018 | 4915 | 0.230 |
Why?
|
| Pandemics | 2 | 2021 | 8656 | 0.220 |
Why?
|
| Prednisone | 30 | 2023 | 1563 | 0.210 |
Why?
|
| Hodgkin Disease | 12 | 2021 | 1378 | 0.210 |
Why?
|
| Continuity of Patient Care | 1 | 2010 | 1069 | 0.210 |
Why?
|
| Healthcare Disparities | 3 | 2020 | 3358 | 0.210 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 3808 | 0.210 |
Why?
|
| Patient Advocacy | 3 | 2015 | 360 | 0.210 |
Why?
|
| Taxoids | 2 | 2018 | 668 | 0.210 |
Why?
|
| Animals | 87 | 2018 | 168475 | 0.200 |
Why?
|
| Botswana | 5 | 2021 | 1048 | 0.200 |
Why?
|
| Folic Acid | 13 | 1997 | 1323 | 0.200 |
Why?
|
| Patient Participation | 4 | 2019 | 1445 | 0.200 |
Why?
|
| Caregivers | 13 | 2011 | 2238 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2018 | 3407 | 0.200 |
Why?
|
| Health Services Accessibility | 5 | 2016 | 5440 | 0.200 |
Why?
|
| Bone Marrow Cells | 8 | 1987 | 2417 | 0.200 |
Why?
|
| Metformin | 1 | 2009 | 906 | 0.200 |
Why?
|
| Kinetics | 37 | 2004 | 6374 | 0.190 |
Why?
|
| Dioxoles | 1 | 2002 | 95 | 0.190 |
Why?
|
| Patient Care Team | 3 | 2008 | 2521 | 0.190 |
Why?
|
| Phosphonoacetic Acid | 4 | 1982 | 54 | 0.190 |
Why?
|
| Leukemia, Lymphoid | 11 | 1983 | 310 | 0.190 |
Why?
|
| Purines | 10 | 1996 | 607 | 0.190 |
Why?
|
| Aspartic Acid | 6 | 1982 | 576 | 0.180 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2011 | 1188 | 0.180 |
Why?
|
| Research | 4 | 2015 | 1982 | 0.180 |
Why?
|
| Drug Costs | 2 | 2015 | 1183 | 0.180 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 16990 | 0.180 |
Why?
|
| Prostatic Neoplasms | 6 | 2012 | 11122 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 8 | 2018 | 9177 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2011 | 3615 | 0.180 |
Why?
|
| Calcium Channel Blockers | 4 | 1995 | 694 | 0.170 |
Why?
|
| Isoquinolines | 1 | 2002 | 352 | 0.170 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 1995 | 718 | 0.170 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 2759 | 0.170 |
Why?
|
| HIV Infections | 6 | 2023 | 17354 | 0.170 |
Why?
|
| Overweight | 1 | 2011 | 2417 | 0.170 |
Why?
|
| Organophosphorus Compounds | 4 | 1982 | 206 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2007 | 1051 | 0.170 |
Why?
|
| DNA, Neoplasm | 9 | 2018 | 1745 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2003 | 857 | 0.170 |
Why?
|
| Bone Marrow | 25 | 2009 | 2911 | 0.160 |
Why?
|
| Education, Medical, Continuing | 2 | 2005 | 823 | 0.160 |
Why?
|
| Mammography | 1 | 2010 | 2430 | 0.160 |
Why?
|
| China | 2 | 2019 | 2374 | 0.160 |
Why?
|
| Hospital-Physician Joint Ventures | 1 | 1999 | 30 | 0.160 |
Why?
|
| Capacity Building | 2 | 2019 | 258 | 0.160 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2002 | 396 | 0.160 |
Why?
|
| Azithromycin | 1 | 2020 | 199 | 0.160 |
Why?
|
| Neoplasm Proteins | 7 | 2016 | 3617 | 0.160 |
Why?
|
| Leucovorin | 13 | 2004 | 643 | 0.150 |
Why?
|
| Heart Failure | 2 | 2013 | 11671 | 0.150 |
Why?
|
| Mass Screening | 3 | 2012 | 5429 | 0.150 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2018 | 79 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2010 | 3462 | 0.150 |
Why?
|
| Carcinogenicity Tests | 1 | 2017 | 38 | 0.150 |
Why?
|
| Peptides | 7 | 1985 | 4358 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2002 | 617 | 0.150 |
Why?
|
| DCMP Deaminase | 3 | 1983 | 7 | 0.150 |
Why?
|
| Granulocytes | 6 | 1987 | 551 | 0.150 |
Why?
|
| Mitosis | 2 | 1994 | 1188 | 0.150 |
Why?
|
| Truth Disclosure | 4 | 2008 | 434 | 0.140 |
Why?
|
| Etoposide | 10 | 2008 | 634 | 0.140 |
Why?
|
| Mountaineering | 2 | 2011 | 45 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2005 | 1351 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 3085 | 0.140 |
Why?
|
| Floxuridine | 10 | 1993 | 44 | 0.140 |
Why?
|
| Melanoma | 5 | 2012 | 5709 | 0.140 |
Why?
|
| Financing, Personal | 1 | 2019 | 309 | 0.140 |
Why?
|
| Terminology as Topic | 1 | 2004 | 1530 | 0.130 |
Why?
|
| Phosphotransferases | 5 | 1978 | 303 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2011 | 12149 | 0.130 |
Why?
|
| Pineal Gland | 4 | 1982 | 158 | 0.130 |
Why?
|
| Suramin | 1 | 1995 | 34 | 0.130 |
Why?
|
| Time Factors | 34 | 2019 | 39969 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2008 | 8554 | 0.130 |
Why?
|
| Holography | 1 | 2016 | 80 | 0.130 |
Why?
|
| Allopurinol | 4 | 1983 | 198 | 0.130 |
Why?
|
| Parathyroid Hormone | 1 | 2002 | 1803 | 0.130 |
Why?
|
| Female | 119 | 2023 | 392705 | 0.130 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 3 | 1980 | 48 | 0.120 |
Why?
|
| Pyridines | 3 | 2020 | 2875 | 0.120 |
Why?
|
| Growth Inhibitors | 2 | 1995 | 378 | 0.120 |
Why?
|
| Massachusetts | 5 | 2019 | 8833 | 0.120 |
Why?
|
| Research Support as Topic | 5 | 2015 | 697 | 0.120 |
Why?
|
| Cytidine Deaminase | 7 | 1982 | 243 | 0.120 |
Why?
|
| Specialization | 3 | 2007 | 778 | 0.120 |
Why?
|
| Cisplatin | 4 | 2016 | 1652 | 0.120 |
Why?
|
| Standard of Care | 1 | 2018 | 551 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 4016 | 0.120 |
Why?
|
| Patient Selection | 4 | 2017 | 4244 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2018 | 2009 | 0.120 |
Why?
|
| Prescription Fees | 1 | 2015 | 153 | 0.110 |
Why?
|
| Leukemia, Myeloid | 10 | 2002 | 694 | 0.110 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2000 | 874 | 0.110 |
Why?
|
| Scientific Misconduct | 1 | 1994 | 74 | 0.110 |
Why?
|
| Prostatectomy | 1 | 2002 | 1824 | 0.110 |
Why?
|
| Cell Line | 25 | 1988 | 15601 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2003 | 1998 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 7 | 2009 | 1334 | 0.110 |
Why?
|
| Alkaloids | 3 | 1991 | 192 | 0.110 |
Why?
|
| Leukemia | 11 | 1995 | 1522 | 0.110 |
Why?
|
| Male | 95 | 2023 | 360846 | 0.110 |
Why?
|
| Indoles | 3 | 2011 | 1833 | 0.110 |
Why?
|
| Azacitidine | 9 | 1987 | 336 | 0.110 |
Why?
|
| Peptide Biosynthesis | 2 | 1982 | 52 | 0.110 |
Why?
|
| Travel | 1 | 2019 | 796 | 0.110 |
Why?
|
| Uridine | 5 | 1982 | 141 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2014 | 5314 | 0.100 |
Why?
|
| Infusion Pumps | 1 | 1993 | 163 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1008 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 5337 | 0.100 |
Why?
|
| Nucleotide Deaminases | 2 | 1983 | 11 | 0.100 |
Why?
|
| Leukemia L1210 | 8 | 1979 | 44 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2002 | 1606 | 0.100 |
Why?
|
| Quinolines | 1 | 2018 | 765 | 0.100 |
Why?
|
| Adenoma, Islet Cell | 1 | 1992 | 72 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 999 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2002 | 5112 | 0.100 |
Why?
|
| Hypoxanthines | 3 | 1981 | 35 | 0.100 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 1992 | 274 | 0.100 |
Why?
|
| Adult | 87 | 2019 | 221210 | 0.100 |
Why?
|
| Vulnerable Populations | 2 | 2015 | 703 | 0.100 |
Why?
|
| Membrane Glycoproteins | 4 | 1991 | 3701 | 0.100 |
Why?
|
| Staining and Labeling | 1 | 2016 | 1085 | 0.100 |
Why?
|
| Intestinal Neoplasms | 1 | 1994 | 314 | 0.100 |
Why?
|
| Brachytherapy | 2 | 2016 | 1223 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2008 | 3816 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 2016 | 0.100 |
Why?
|
| Neoplasms, Experimental | 9 | 1998 | 1229 | 0.100 |
Why?
|
| Pneumonia, Pneumocystis | 5 | 1988 | 242 | 0.100 |
Why?
|
| Medicine | 3 | 2007 | 942 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2014 | 590 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 610 | 0.090 |
Why?
|
| Ovarian Neoplasms | 14 | 2012 | 4878 | 0.090 |
Why?
|
| Lawyers | 1 | 2011 | 38 | 0.090 |
Why?
|
| Appointments and Schedules | 1 | 2015 | 443 | 0.090 |
Why?
|
| Middle Aged | 79 | 2023 | 220921 | 0.090 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 6815 | 0.090 |
Why?
|
| Cytidine | 7 | 1996 | 64 | 0.090 |
Why?
|
| Fluorodeoxyuridylate | 7 | 1991 | 7 | 0.090 |
Why?
|
| Tandem Repeat Sequences | 1 | 2011 | 180 | 0.090 |
Why?
|
| Staurosporine | 1 | 2011 | 242 | 0.090 |
Why?
|
| Hospitals, General | 2 | 2013 | 798 | 0.090 |
Why?
|
| Benzothiazoles | 1 | 2011 | 247 | 0.090 |
Why?
|
| Toxoplasma | 5 | 1990 | 157 | 0.090 |
Why?
|
| Piperazines | 1 | 2001 | 2523 | 0.090 |
Why?
|
| Furans | 1 | 2011 | 202 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3514 | 0.090 |
Why?
|
| Leukocytes | 8 | 1978 | 2026 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 1897 | 0.080 |
Why?
|
| Carbazoles | 1 | 2011 | 220 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3597 | 0.080 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 2 | 1988 | 18 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2009 | 10766 | 0.080 |
Why?
|
| Survival Rate | 7 | 2012 | 12723 | 0.080 |
Why?
|
| Thymidine | 8 | 1987 | 299 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 2 | 2011 | 1380 | 0.080 |
Why?
|
| Procarbazine | 13 | 1990 | 172 | 0.080 |
Why?
|
| Health Personnel | 2 | 2022 | 3335 | 0.080 |
Why?
|
| Infusions, Parenteral | 9 | 1995 | 397 | 0.080 |
Why?
|
| Flavones | 1 | 2009 | 68 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 2 | 2012 | 2469 | 0.080 |
Why?
|
| Obesity | 1 | 2011 | 12947 | 0.080 |
Why?
|
| Cell Survival | 8 | 1996 | 5791 | 0.080 |
Why?
|
| Nobel Prize | 1 | 1988 | 48 | 0.080 |
Why?
|
| Carcinogens | 2 | 1988 | 452 | 0.080 |
Why?
|
| Bleomycin | 9 | 1992 | 494 | 0.080 |
Why?
|
| Injections | 1 | 2011 | 831 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2017 | 1126 | 0.080 |
Why?
|
| Epidemics | 1 | 2014 | 512 | 0.080 |
Why?
|
| Cell Division | 8 | 1986 | 4465 | 0.080 |
Why?
|
| Drug Interactions | 10 | 1992 | 1416 | 0.080 |
Why?
|
| Camptothecin | 1 | 1992 | 591 | 0.080 |
Why?
|
| Deoxyuridine | 6 | 1986 | 34 | 0.080 |
Why?
|
| Tetrahydrofolates | 2 | 1993 | 58 | 0.080 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 395 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 529 | 0.070 |
Why?
|
| Phorbol Esters | 1 | 1988 | 108 | 0.070 |
Why?
|
| Sister Chromatid Exchange | 1 | 1987 | 60 | 0.070 |
Why?
|
| Melatonin | 4 | 1982 | 669 | 0.070 |
Why?
|
| Gene Amplification | 4 | 1987 | 1089 | 0.070 |
Why?
|
| Journalism, Medical | 1 | 2008 | 73 | 0.070 |
Why?
|
| Acyltransferases | 2 | 1988 | 305 | 0.070 |
Why?
|
| Pyridoxal Phosphate | 5 | 1971 | 121 | 0.070 |
Why?
|
| Binding, Competitive | 8 | 1986 | 1141 | 0.070 |
Why?
|
| Terminal Care | 3 | 2005 | 1761 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1993 | 1092 | 0.070 |
Why?
|
| Government Regulation | 1 | 2011 | 524 | 0.070 |
Why?
|
| Medical Audit | 1 | 2008 | 453 | 0.070 |
Why?
|
| Nucleoside Deaminases | 2 | 1978 | 58 | 0.070 |
Why?
|
| Tetrahydrouridine | 4 | 1982 | 5 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 14665 | 0.070 |
Why?
|
| Cyclin D1 | 1 | 2009 | 451 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 3 | 1987 | 3397 | 0.070 |
Why?
|
| Acetylation | 1 | 2009 | 1055 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 20100 | 0.070 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2009 | 424 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1992 | 732 | 0.070 |
Why?
|
| Boston | 7 | 2015 | 9327 | 0.070 |
Why?
|
| Adaptation, Psychological | 5 | 2011 | 2629 | 0.070 |
Why?
|
| Palliative Care | 7 | 2005 | 3598 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2017 | 7968 | 0.070 |
Why?
|
| Radioligand Assay | 3 | 1985 | 366 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 7 | 2009 | 6131 | 0.070 |
Why?
|
| Laughter Therapy | 1 | 2005 | 3 | 0.070 |
Why?
|
| Pteroylpolyglutamic Acids | 1 | 1985 | 9 | 0.060 |
Why?
|
| Cell Separation | 6 | 1987 | 1720 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1990 | 621 | 0.060 |
Why?
|
| Blood Cells | 1 | 1987 | 305 | 0.060 |
Why?
|
| Inosine | 3 | 1985 | 130 | 0.060 |
Why?
|
| Rosette Formation | 1 | 1985 | 152 | 0.060 |
Why?
|
| Wit and Humor as Topic | 1 | 2005 | 31 | 0.060 |
Why?
|
| Carboxypeptidases | 4 | 1972 | 154 | 0.060 |
Why?
|
| Germinal Center | 1 | 2008 | 380 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 2 | 2002 | 940 | 0.060 |
Why?
|
| Genomics | 2 | 2016 | 5821 | 0.060 |
Why?
|
| Editorial Policies | 1 | 2010 | 458 | 0.060 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 720 | 0.060 |
Why?
|
| Treatment Outcome | 12 | 2018 | 64685 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 3878 | 0.060 |
Why?
|
| Legislation, Drug | 1 | 2007 | 214 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 6534 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 10 | 1988 | 1541 | 0.060 |
Why?
|
| Liver Neoplasms | 9 | 2010 | 4317 | 0.060 |
Why?
|
| Trimetrexate | 10 | 1989 | 15 | 0.060 |
Why?
|
| Sports | 1 | 2011 | 705 | 0.060 |
Why?
|
| Mice | 30 | 2015 | 81539 | 0.060 |
Why?
|
| Physician's Role | 2 | 2002 | 917 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2015 | 2690 | 0.060 |
Why?
|
| Pneumocystis | 3 | 1989 | 55 | 0.060 |
Why?
|
| Aminohydrolases | 2 | 1974 | 18 | 0.060 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2004 | 17 | 0.060 |
Why?
|
| Sarcoma 180 | 2 | 1982 | 6 | 0.060 |
Why?
|
| Sulfonamides | 2 | 2011 | 1979 | 0.060 |
Why?
|
| Patients | 1 | 2011 | 907 | 0.060 |
Why?
|
| Colonic Neoplasms | 4 | 2012 | 2539 | 0.060 |
Why?
|
| Aged | 43 | 2019 | 169310 | 0.060 |
Why?
|
| Drug Administration Schedule | 10 | 1993 | 4853 | 0.060 |
Why?
|
| Professional-Family Relations | 1 | 2008 | 495 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2005 | 629 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2018 | 12341 | 0.060 |
Why?
|
| Pseudomonas | 3 | 1972 | 124 | 0.060 |
Why?
|
| Marketing of Health Services | 2 | 2002 | 151 | 0.060 |
Why?
|
| Lymphokines | 1 | 1987 | 927 | 0.060 |
Why?
|
| Metaphor | 1 | 2004 | 41 | 0.060 |
Why?
|
| Campylobacter Infections | 1 | 1983 | 31 | 0.060 |
Why?
|
| Deoxyuracil Nucleotides | 2 | 1982 | 13 | 0.060 |
Why?
|
| Interprofessional Relations | 4 | 2003 | 990 | 0.050 |
Why?
|
| Drug Therapy, Combination | 29 | 1988 | 6312 | 0.050 |
Why?
|
| Biological Assay | 3 | 2002 | 626 | 0.050 |
Why?
|
| Oxypurinol | 2 | 1980 | 8 | 0.050 |
Why?
|
| Attitude of Health Personnel | 5 | 2011 | 3889 | 0.050 |
Why?
|
| Risk | 4 | 2009 | 9610 | 0.050 |
Why?
|
| Uridine Kinase | 3 | 1977 | 6 | 0.050 |
Why?
|
| Oncology Service, Hospital | 1 | 2003 | 57 | 0.050 |
Why?
|
| Thrombophlebitis | 1 | 1983 | 289 | 0.050 |
Why?
|
| Half-Life | 8 | 1988 | 651 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 1386 | 0.050 |
Why?
|
| Molecular Weight | 6 | 1986 | 2186 | 0.050 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2007 | 452 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
| Self-Help Groups | 1 | 2004 | 192 | 0.050 |
Why?
|
| Identity Crisis | 1 | 2002 | 12 | 0.050 |
Why?
|
| Drug Monitoring | 3 | 2002 | 962 | 0.050 |
Why?
|
| Benz(a)Anthracenes | 1 | 1981 | 11 | 0.050 |
Why?
|
| Marketing | 1 | 2004 | 220 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
| Faith Healing | 1 | 2002 | 26 | 0.050 |
Why?
|
| Postmenopause | 1 | 2011 | 2513 | 0.050 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 1981 | 58 | 0.050 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2008 | 829 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1993 | 4352 | 0.050 |
Why?
|
| Remission, Spontaneous | 19 | 1979 | 384 | 0.050 |
Why?
|
| Consumer Product Safety | 1 | 2002 | 122 | 0.050 |
Why?
|
| Developing Countries | 1 | 2014 | 2885 | 0.050 |
Why?
|
| Industry | 1 | 2004 | 364 | 0.050 |
Why?
|
| Erythema | 1 | 1983 | 262 | 0.050 |
Why?
|
| Cells, Cultured | 14 | 1995 | 18966 | 0.050 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2002 | 81 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2008 | 1498 | 0.050 |
Why?
|
| Mechlorethamine | 6 | 1983 | 129 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 161 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 3 | 1987 | 352 | 0.050 |
Why?
|
| Quality of Life | 8 | 2011 | 13367 | 0.050 |
Why?
|
| Mental Healing | 1 | 2001 | 28 | 0.050 |
Why?
|
| Models, Biological | 2 | 2009 | 9469 | 0.050 |
Why?
|
| Attitude | 2 | 2004 | 775 | 0.050 |
Why?
|
| Lymphography | 5 | 1980 | 188 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2013 | 1853 | 0.050 |
Why?
|
| Genes, abl | 1 | 2001 | 69 | 0.050 |
Why?
|
| Health Promotion | 1 | 2013 | 2214 | 0.050 |
Why?
|
| Cost of Illness | 2 | 2022 | 1937 | 0.050 |
Why?
|
| Religion | 2 | 2002 | 372 | 0.050 |
Why?
|
| Aspartate Carbamoyltransferase | 1 | 1980 | 19 | 0.040 |
Why?
|
| Protein Binding | 9 | 1993 | 9353 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 1986 | 2827 | 0.040 |
Why?
|
| Inosine Nucleotides | 1 | 1980 | 1 | 0.040 |
Why?
|
| Information Services | 1 | 2002 | 236 | 0.040 |
Why?
|
| Internet | 2 | 2004 | 3093 | 0.040 |
Why?
|
| Inosine Monophosphate | 1 | 1980 | 7 | 0.040 |
Why?
|
| Accreditation | 1 | 2004 | 473 | 0.040 |
Why?
|
| Vinblastine | 3 | 1991 | 488 | 0.040 |
Why?
|
| Body Weight | 1 | 2011 | 4618 | 0.040 |
Why?
|
| Prognosis | 15 | 2008 | 29629 | 0.040 |
Why?
|
| Social Support | 2 | 2008 | 2172 | 0.040 |
Why?
|
| Combined Modality Therapy | 4 | 1998 | 8527 | 0.040 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 1980 | 56 | 0.040 |
Why?
|
| Survivors | 1 | 2011 | 2371 | 0.040 |
Why?
|
| Alkylating Agents | 5 | 1984 | 133 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 8 | 1983 | 2496 | 0.040 |
Why?
|
| Helminth Proteins | 1 | 2000 | 173 | 0.040 |
Why?
|
| Apoptosis | 3 | 2009 | 9490 | 0.040 |
Why?
|
| Biotechnology | 1 | 2002 | 282 | 0.040 |
Why?
|
| Myocardium | 1 | 2012 | 4725 | 0.040 |
Why?
|
| Neoplasm Staging | 9 | 1994 | 11120 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 1984 | 678 | 0.040 |
Why?
|
| Decision Making | 7 | 2003 | 3929 | 0.040 |
Why?
|
| Hemangioendothelioma | 1 | 2000 | 111 | 0.040 |
Why?
|
| Hormones | 2 | 2020 | 869 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1981 | 410 | 0.040 |
Why?
|
| Nurses | 1 | 2008 | 2478 | 0.040 |
Why?
|
| Central Nervous System | 3 | 2020 | 1336 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1981 | 507 | 0.040 |
Why?
|
| Pain, Intractable | 1 | 2000 | 132 | 0.040 |
Why?
|
| Adolescent | 28 | 2018 | 88326 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 3 | 2003 | 2894 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2008 | 1590 | 0.040 |
Why?
|
| General Surgery | 2 | 1994 | 1692 | 0.040 |
Why?
|
| Nucleoside-Phosphate Kinase | 1 | 1978 | 24 | 0.040 |
Why?
|
| Health Facility Merger | 1 | 1999 | 47 | 0.040 |
Why?
|
| Methyltransferases | 2 | 1985 | 377 | 0.040 |
Why?
|
| Tissue Distribution | 5 | 1983 | 2264 | 0.040 |
Why?
|
| Defibrillators, Implantable | 1 | 2008 | 1490 | 0.040 |
Why?
|
| Carcinoma, Brown-Pearce | 1 | 1977 | 3 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 794 | 0.040 |
Why?
|
| Insulin | 2 | 2011 | 6597 | 0.040 |
Why?
|
| Biological Transport | 5 | 1993 | 2091 | 0.040 |
Why?
|
| Spleen | 4 | 1981 | 2295 | 0.040 |
Why?
|
| Sexuality | 1 | 2000 | 180 | 0.040 |
Why?
|
| South Africa | 1 | 2023 | 1843 | 0.040 |
Why?
|
| Purpura | 1 | 1978 | 117 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3201 | 0.040 |
Why?
|
| Cryptococcosis | 1 | 1978 | 104 | 0.040 |
Why?
|
| Laparotomy | 5 | 1980 | 457 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 883 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2010 | 8633 | 0.040 |
Why?
|
| Bereavement | 1 | 2002 | 308 | 0.040 |
Why?
|
| Libraries, Digital | 1 | 2017 | 6 | 0.040 |
Why?
|
| Maytansine | 1 | 1978 | 86 | 0.040 |
Why?
|
| Liver | 15 | 1981 | 7528 | 0.040 |
Why?
|
| Radiography | 1 | 2008 | 6965 | 0.040 |
Why?
|
| Anilides | 1 | 2020 | 411 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 2297 | 0.040 |
Why?
|
| Formyltetrahydrofolates | 2 | 1987 | 2 | 0.040 |
Why?
|
| Cause of Death | 2 | 2010 | 3683 | 0.040 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 1977 | 30 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 1999 | 605 | 0.040 |
Why?
|
| Drug Synergism | 4 | 2009 | 1757 | 0.030 |
Why?
|
| Parent-Child Relations | 1 | 2002 | 761 | 0.030 |
Why?
|
| Africa | 1 | 2019 | 709 | 0.030 |
Why?
|
| Advance Directives | 1 | 1999 | 249 | 0.030 |
Why?
|
| Methods | 4 | 1985 | 1067 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2009 | 10451 | 0.030 |
Why?
|
| Corynebacterium | 1 | 1976 | 48 | 0.030 |
Why?
|
| Corynebacterium Infections | 1 | 1976 | 27 | 0.030 |
Why?
|
| Thalidomide | 1 | 2002 | 885 | 0.030 |
Why?
|
| Osteosarcoma | 3 | 1999 | 897 | 0.030 |
Why?
|
| Complementary Therapies | 1 | 2001 | 486 | 0.030 |
Why?
|
| Ribonucleosides | 1 | 1976 | 79 | 0.030 |
Why?
|
| Aminopterin | 1 | 1976 | 15 | 0.030 |
Why?
|
| Toxoplasmosis | 2 | 1987 | 94 | 0.030 |
Why?
|
| Carcinoma, Ehrlich Tumor | 1 | 1976 | 23 | 0.030 |
Why?
|
| Terminally Ill | 1 | 1999 | 240 | 0.030 |
Why?
|
| Resuscitation Orders | 1 | 1999 | 270 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 1999 | 696 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 1999 | 318 | 0.030 |
Why?
|
| Hemangiosarcoma | 1 | 1979 | 215 | 0.030 |
Why?
|
| Ligands | 2 | 2000 | 3272 | 0.030 |
Why?
|
| Nitrosourea Compounds | 5 | 1977 | 32 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2000 | 357 | 0.030 |
Why?
|
| Cytokines | 1 | 2011 | 7396 | 0.030 |
Why?
|
| Uracil Nucleotides | 1 | 1975 | 13 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2021 | 858 | 0.030 |
Why?
|
| Intracellular Fluid | 2 | 1987 | 201 | 0.030 |
Why?
|
| Binding Sites | 6 | 1983 | 6056 | 0.030 |
Why?
|
| Fear | 1 | 2005 | 1477 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2000 | 764 | 0.030 |
Why?
|
| Family Health | 4 | 2003 | 1257 | 0.030 |
Why?
|
| Injections, Intravenous | 10 | 1988 | 1379 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2001 | 686 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2000 | 627 | 0.030 |
Why?
|
| Genetic Techniques | 1 | 1998 | 428 | 0.030 |
Why?
|
| Oxazines | 1 | 1978 | 350 | 0.030 |
Why?
|
| Burnout, Professional | 2 | 2003 | 704 | 0.030 |
Why?
|
| Cocaine-Related Disorders | 1 | 1999 | 461 | 0.030 |
Why?
|
| Gallium Radioisotopes | 1 | 1976 | 195 | 0.030 |
Why?
|
| HIV-1 | 1 | 2013 | 6863 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2009 | 3208 | 0.030 |
Why?
|
| Aged, 80 and over | 6 | 2013 | 58984 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1976 | 1972 | 0.030 |
Why?
|
| Young Adult | 2 | 2013 | 59260 | 0.030 |
Why?
|
| Benzamides | 1 | 2001 | 1371 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 461 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2002 | 1301 | 0.030 |
Why?
|
| Gene Expression | 1 | 2008 | 7581 | 0.030 |
Why?
|
| Forefoot, Human | 1 | 2014 | 31 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 3 | 1986 | 361 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 1158 | 0.030 |
Why?
|
| Clinical Enzyme Tests | 1 | 1974 | 113 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 5672 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 1999 | 4024 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 1996 | 233 | 0.030 |
Why?
|
| Depression, Chemical | 4 | 1975 | 184 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 1999 | 1156 | 0.030 |
Why?
|
| Access to Information | 1 | 2017 | 316 | 0.030 |
Why?
|
| Mediastinal Neoplasms | 1 | 1977 | 401 | 0.030 |
Why?
|
| Counseling | 1 | 2002 | 1547 | 0.030 |
Why?
|
| Vitamin B 6 Deficiency | 2 | 1970 | 18 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2020 | 9280 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 2319 | 0.030 |
Why?
|
| Biological Transport, Active | 2 | 1985 | 328 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2011 | 12953 | 0.030 |
Why?
|
| Stress, Psychological | 4 | 2003 | 4481 | 0.030 |
Why?
|
| Immunotherapy, Active | 1 | 1993 | 59 | 0.030 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 1972 | 8 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 3713 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2014 | 236 | 0.030 |
Why?
|
| Prospective Studies | 11 | 2019 | 54423 | 0.030 |
Why?
|
| Microspheres | 1 | 2016 | 784 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 1858 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 7406 | 0.030 |
Why?
|
| Conjunctivitis | 1 | 1974 | 155 | 0.030 |
Why?
|
| Multiple Myeloma | 2 | 2009 | 5146 | 0.030 |
Why?
|
| Administration, Oral | 9 | 1988 | 4021 | 0.030 |
Why?
|
| Chromatography, Gel | 4 | 1982 | 646 | 0.030 |
Why?
|
| Structure-Activity Relationship | 5 | 2002 | 3076 | 0.030 |
Why?
|
| Intestinal Mucosa | 3 | 1985 | 3032 | 0.030 |
Why?
|
| Medical Errors | 1 | 2001 | 1263 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6484 | 0.030 |
Why?
|
| Stem Cells | 1 | 1985 | 3524 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2015 | 23447 | 0.030 |
Why?
|
| Eyelid Diseases | 1 | 1974 | 157 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2008 | 694 | 0.020 |
Why?
|
| Spinal Neoplasms | 1 | 1999 | 716 | 0.020 |
Why?
|
| Data Collection | 1 | 2021 | 3322 | 0.020 |
Why?
|
| Cross-Over Studies | 2 | 1995 | 2079 | 0.020 |
Why?
|
| Meninges | 1 | 1973 | 198 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 1179 | 0.020 |
Why?
|
| Streptozocin | 1 | 1992 | 194 | 0.020 |
Why?
|
| Reminder Systems | 1 | 2015 | 388 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 4 | 1988 | 201 | 0.020 |
Why?
|
| Sample Size | 1 | 2015 | 841 | 0.020 |
Why?
|
| Adenocarcinoma | 6 | 1999 | 6345 | 0.020 |
Why?
|
| Tryptophan | 2 | 1971 | 482 | 0.020 |
Why?
|
| Telephone | 1 | 2015 | 627 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 1118 | 0.020 |
Why?
|
| Education, Medical | 1 | 2003 | 1725 | 0.020 |
Why?
|
| Tyrosine Decarboxylase | 1 | 1970 | 2 | 0.020 |
Why?
|
| Lymph Nodes | 6 | 2016 | 3465 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2019 | 2495 | 0.020 |
Why?
|
| Empathy | 2 | 2005 | 473 | 0.020 |
Why?
|
| Biopsy | 11 | 1982 | 6766 | 0.020 |
Why?
|
| Antimetabolites | 1 | 1991 | 129 | 0.020 |
Why?
|
| Collagen | 1 | 1999 | 2638 | 0.020 |
Why?
|
| Deoxycytidine Monophosphate | 2 | 1981 | 4 | 0.020 |
Why?
|
| Income | 1 | 2019 | 1877 | 0.020 |
Why?
|
| Dihydropteroate Synthase | 1 | 1990 | 27 | 0.020 |
Why?
|
| Porphyrias | 1 | 1970 | 57 | 0.020 |
Why?
|
| Transferases | 1 | 1990 | 72 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 2 | 1998 | 2645 | 0.020 |
Why?
|
| 3-Deazauridine | 2 | 1980 | 2 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2014 | 787 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 9032 | 0.020 |
Why?
|
| Glucagon | 1 | 1972 | 532 | 0.020 |
Why?
|
| Phosphoribosylaminoimidazolecarboxamide Formyltransferase | 2 | 1988 | 2 | 0.020 |
Why?
|
| Ovary | 3 | 1978 | 959 | 0.020 |
Why?
|
| Biotransformation | 2 | 1980 | 166 | 0.020 |
Why?
|
| DNA Repair | 2 | 1996 | 2046 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 1974 | 622 | 0.020 |
Why?
|
| Leukocyte Count | 5 | 1995 | 1596 | 0.020 |
Why?
|
| Economics | 1 | 1990 | 141 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 1970 | 452 | 0.020 |
Why?
|
| Teratoma | 1 | 1972 | 404 | 0.020 |
Why?
|
| Terpenes | 1 | 1989 | 96 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2009 | 53 | 0.020 |
Why?
|
| Leukemia, Experimental | 2 | 1981 | 225 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1994 | 1702 | 0.020 |
Why?
|
| Sepsis | 1 | 1983 | 2585 | 0.020 |
Why?
|
| Intestinal Absorption | 2 | 1981 | 400 | 0.020 |
Why?
|
| Tubulin | 1 | 1993 | 693 | 0.020 |
Why?
|
| DNA Damage | 2 | 1996 | 2449 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 7828 | 0.020 |
Why?
|
| Laparoscopy | 7 | 1978 | 2036 | 0.020 |
Why?
|
| Rats, Inbred Strains | 3 | 1988 | 2088 | 0.020 |
Why?
|
| Canada | 1 | 1994 | 2122 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 5493 | 0.020 |
Why?
|
| Italy | 1 | 1991 | 842 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 1999 | 2048 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1989 | 122 | 0.020 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2003 | 258 | 0.020 |
Why?
|
| Macromolecular Substances | 3 | 1985 | 1434 | 0.020 |
Why?
|
| Ligases | 1 | 1970 | 333 | 0.020 |
Why?
|
| Clone Cells | 2 | 1988 | 1659 | 0.020 |
Why?
|
| Child | 17 | 2005 | 80158 | 0.020 |
Why?
|
| NADP | 2 | 1987 | 227 | 0.020 |
Why?
|
| Risk Factors | 3 | 2011 | 74213 | 0.020 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 1988 | 41 | 0.020 |
Why?
|
| Enzyme Activation | 4 | 1981 | 3597 | 0.020 |
Why?
|
| Thymine Nucleotides | 2 | 1981 | 57 | 0.020 |
Why?
|
| Benzoates | 1 | 1969 | 212 | 0.020 |
Why?
|
| Species Specificity | 2 | 1990 | 2414 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 1977 | 917 | 0.020 |
Why?
|
| Blotting, Western | 3 | 2009 | 5035 | 0.020 |
Why?
|
| Rats | 9 | 1989 | 23741 | 0.020 |
Why?
|
| Hydrazines | 1 | 1969 | 224 | 0.020 |
Why?
|
| Tritium | 3 | 1973 | 708 | 0.020 |
Why?
|
| Receptors, Cell Surface | 2 | 1993 | 2822 | 0.020 |
Why?
|
| Benzene Derivatives | 1 | 1987 | 53 | 0.020 |
Why?
|
| Deoxycytidine | 3 | 1999 | 877 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1977 | 1796 | 0.020 |
Why?
|
| Cattle | 3 | 1980 | 3849 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 1995 | 2707 | 0.020 |
Why?
|
| Deoxyribonucleosides | 1 | 1987 | 7 | 0.020 |
Why?
|
| Suicide | 1 | 1999 | 1602 | 0.020 |
Why?
|
| Nitrendipine | 1 | 1987 | 12 | 0.020 |
Why?
|
| Toxoplasmosis, Animal | 1 | 1987 | 18 | 0.020 |
Why?
|
| Pentose Phosphate Pathway | 1 | 1987 | 126 | 0.020 |
Why?
|
| Professional-Patient Relations | 2 | 2005 | 726 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2009 | 8321 | 0.020 |
Why?
|
| Chromosome Aberrations | 3 | 1995 | 1768 | 0.020 |
Why?
|
| Body Temperature Regulation | 1 | 1969 | 292 | 0.020 |
Why?
|
| Treatment Refusal | 2 | 2002 | 429 | 0.020 |
Why?
|
| Lymphatic Metastasis | 6 | 1978 | 2915 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 1991 | 1704 | 0.020 |
Why?
|
| Glutamates | 3 | 1985 | 389 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1979 | 297 | 0.020 |
Why?
|
| Aging | 3 | 1996 | 8710 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1991 | 1171 | 0.020 |
Why?
|
| Melphalan | 3 | 1978 | 420 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2000 | 3537 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2008 | 20568 | 0.020 |
Why?
|
| Specialty Boards | 1 | 1988 | 235 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 14608 | 0.020 |
Why?
|
| Aminoacridines | 1 | 1986 | 9 | 0.020 |
Why?
|
| Platelet Count | 2 | 2002 | 781 | 0.020 |
Why?
|
| Amsacrine | 1 | 1986 | 19 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2002 | 23996 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 2010 | 528 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 1972 | 799 | 0.020 |
Why?
|
| Charcoal | 1 | 1986 | 67 | 0.020 |
Why?
|
| Nervous System Diseases | 2 | 1973 | 1667 | 0.020 |
Why?
|
| Mortality | 1 | 1997 | 2902 | 0.020 |
Why?
|
| Calmodulin | 1 | 1987 | 218 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1975 | 2413 | 0.020 |
Why?
|
| Adsorption | 1 | 1986 | 197 | 0.020 |
Why?
|
| Antiviral Agents | 2 | 2010 | 3060 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1985 | 115 | 0.020 |
Why?
|
| Bone Neoplasms | 6 | 2003 | 2529 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1994 | 1157 | 0.020 |
Why?
|
| Carbon Radioisotopes | 2 | 1980 | 561 | 0.020 |
Why?
|
| Bone Diseases | 1 | 1969 | 418 | 0.020 |
Why?
|
| Caspases | 1 | 2009 | 879 | 0.020 |
Why?
|
| Survival Analysis | 4 | 2004 | 10090 | 0.020 |
Why?
|
| Cyclohexanes | 3 | 1975 | 152 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2001 | 4331 | 0.020 |
Why?
|
| Leukopenia | 3 | 1983 | 213 | 0.020 |
Why?
|
| Equipment Design | 1 | 1993 | 3511 | 0.020 |
Why?
|
| Peptide Synthases | 1 | 1985 | 80 | 0.020 |
Why?
|
| Hospice Care | 2 | 2003 | 678 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1988 | 385 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2009 | 672 | 0.020 |
Why?
|
| Cricetinae | 2 | 1987 | 2423 | 0.020 |
Why?
|
| Zidovudine | 1 | 1987 | 624 | 0.020 |
Why?
|
| Certification | 1 | 1988 | 418 | 0.020 |
Why?
|
| Blood Proteins | 3 | 1975 | 1173 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2005 | 5882 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 1999 | 2947 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1999 | 3206 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 1027 | 0.010 |
Why?
|
| Altretamine | 3 | 1978 | 11 | 0.010 |
Why?
|
| Boronic Acids | 1 | 2009 | 915 | 0.010 |
Why?
|
| Adenosine Triphosphate | 2 | 1988 | 1989 | 0.010 |
Why?
|
| Trimethoprim | 3 | 1989 | 78 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1991 | 2112 | 0.010 |
Why?
|
| Karyotyping | 1 | 1986 | 1171 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 1987 | 730 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 1987 | 376 | 0.010 |
Why?
|
| Poverty | 1 | 2016 | 2697 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 6938 | 0.010 |
Why?
|
| Campylobacter fetus | 1 | 1983 | 6 | 0.010 |
Why?
|
| Ascites | 2 | 1978 | 338 | 0.010 |
Why?
|
| Training Support | 1 | 1984 | 109 | 0.010 |
Why?
|
| DNA | 5 | 1997 | 7213 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2009 | 2626 | 0.010 |
Why?
|
| Creatinine | 2 | 1981 | 1899 | 0.010 |
Why?
|
| Acute Disease | 3 | 2002 | 7237 | 0.010 |
Why?
|
| Forecasting | 1 | 1992 | 2928 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 3 | 1979 | 413 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 2 | 1976 | 825 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2015 | 3905 | 0.010 |
Why?
|
| Sarcoma | 3 | 1995 | 1801 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 1972 | 1376 | 0.010 |
Why?
|
| Interferons | 1 | 1987 | 706 | 0.010 |
Why?
|
| Religion and Medicine | 1 | 2005 | 161 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2009 | 1330 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1988 | 1202 | 0.010 |
Why?
|
| Osteoma, Osteoid | 1 | 1983 | 90 | 0.010 |
Why?
|
| Pyrazines | 1 | 2009 | 1202 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 18255 | 0.010 |
Why?
|
| Brain | 2 | 1980 | 27121 | 0.010 |
Why?
|
| Haplorhini | 2 | 1981 | 525 | 0.010 |
Why?
|
| Carcinoma 256, Walker | 2 | 1972 | 38 | 0.010 |
Why?
|
| Thioguanine | 3 | 1992 | 45 | 0.010 |
Why?
|
| Solubility | 2 | 1987 | 1091 | 0.010 |
Why?
|
| Cell Membrane | 2 | 1983 | 3687 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2015 | 2499 | 0.010 |
Why?
|
| Cells | 1 | 1983 | 165 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2009 | 3088 | 0.010 |
Why?
|
| Humanism | 1 | 2003 | 86 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10508 | 0.010 |
Why?
|
| Kidney | 6 | 1981 | 7048 | 0.010 |
Why?
|
| Psychology | 1 | 2004 | 356 | 0.010 |
Why?
|
| Christianity | 1 | 2002 | 50 | 0.010 |
Why?
|
| Sodium Azide | 1 | 1981 | 24 | 0.010 |
Why?
|
| Mice, Inbred Strains | 2 | 1976 | 1762 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1985 | 962 | 0.010 |
Why?
|
| Estrogens | 2 | 1978 | 1522 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2009 | 2919 | 0.010 |
Why?
|
| Phosphates | 2 | 1975 | 770 | 0.010 |
Why?
|
| Blood Cell Count | 3 | 1977 | 397 | 0.010 |
Why?
|
| Azides | 1 | 1981 | 118 | 0.010 |
Why?
|
| Xanthines | 1 | 1981 | 120 | 0.010 |
Why?
|
| Tamoxifen | 1 | 1986 | 965 | 0.010 |
Why?
|
| Internal Medicine | 1 | 1988 | 1051 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2002 | 200 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 1935 | 0.010 |
Why?
|
| Age Factors | 5 | 2002 | 18399 | 0.010 |
Why?
|
| Injections, Spinal | 3 | 1982 | 318 | 0.010 |
Why?
|
| Azauridine | 1 | 1980 | 2 | 0.010 |
Why?
|
| Financing, Government | 1 | 1984 | 472 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2009 | 2932 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 2386 | 0.010 |
Why?
|
| Social Conditions | 1 | 2001 | 120 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2005 | 1835 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1995 | 12794 | 0.010 |
Why?
|
| Negotiating | 1 | 2002 | 150 | 0.010 |
Why?
|
| Nurse's Role | 1 | 2002 | 188 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 3779 | 0.010 |
Why?
|
| Circadian Rhythm | 2 | 1982 | 2576 | 0.010 |
Why?
|
| Biological Availability | 3 | 1988 | 390 | 0.010 |
Why?
|
| 4-Aminobenzoic Acid | 2 | 1990 | 22 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2015 | 5079 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1987 | 1889 | 0.010 |
Why?
|
| Electronic Mail | 1 | 2002 | 213 | 0.010 |
Why?
|
| Spirituality | 1 | 2005 | 425 | 0.010 |
Why?
|
| Rabbits | 3 | 1991 | 4772 | 0.010 |
Why?
|
| Calcinosis | 2 | 1978 | 1469 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 1980 | 173 | 0.010 |
Why?
|
| Xanthine Oxidase | 1 | 1980 | 69 | 0.010 |
Why?
|
| HIV | 1 | 1987 | 1582 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1993 | 4937 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1980 | 311 | 0.010 |
Why?
|
| Prolactin | 1 | 1981 | 625 | 0.010 |
Why?
|
| Family Relations | 1 | 2002 | 317 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 1987 | 7859 | 0.010 |
Why?
|
| Sulfamethoxazole | 2 | 1989 | 51 | 0.010 |
Why?
|
| Thorium Dioxide | 1 | 1979 | 20 | 0.010 |
Why?
|
| Vinyl Chloride | 1 | 1979 | 15 | 0.010 |
Why?
|
| Carbon Isotopes | 2 | 1970 | 458 | 0.010 |
Why?
|
| Cladribine | 1 | 1999 | 34 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 1999 | 52 | 0.010 |
Why?
|
| Crack Cocaine | 1 | 1999 | 32 | 0.010 |
Why?
|
| Incidence | 1 | 1997 | 21355 | 0.010 |
Why?
|
| Child Behavior | 1 | 2005 | 847 | 0.010 |
Why?
|
| Virus Replication | 1 | 1987 | 2435 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1987 | 2203 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 4 | 1990 | 6214 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1978 | 20 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1979 | 861 | 0.010 |
Why?
|
| Digestive System | 1 | 1979 | 244 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 1980 | 395 | 0.010 |
Why?
|
| Recurrence | 7 | 1995 | 8466 | 0.010 |
Why?
|
| Pyrimidine Nucleotides | 1 | 1978 | 7 | 0.010 |
Why?
|
| Arsenicals | 1 | 1979 | 118 | 0.010 |
Why?
|
| Sulfhydryl Reagents | 1 | 1978 | 32 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 1987 | 1089 | 0.010 |
Why?
|
| Endostatins | 1 | 1999 | 168 | 0.010 |
Why?
|
| Pain | 3 | 2003 | 5073 | 0.010 |
Why?
|
| Suicide, Assisted | 1 | 1999 | 68 | 0.010 |
Why?
|
| Radium | 1 | 1979 | 72 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1978 | 155 | 0.010 |
Why?
|
| Thrombocytopenia | 4 | 1981 | 1182 | 0.010 |
Why?
|
| Chemistry | 2 | 1975 | 347 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 1972 | 3964 | 0.010 |
Why?
|
| Drug Contamination | 1 | 1979 | 152 | 0.010 |
Why?
|
| Carmustine | 2 | 1975 | 138 | 0.010 |
Why?
|
| Chemical Phenomena | 2 | 1975 | 507 | 0.010 |
Why?
|
| Pregnancy, Multiple | 1 | 1999 | 215 | 0.010 |
Why?
|
| Sulfadiazine | 2 | 1987 | 18 | 0.010 |
Why?
|
| Triazenes | 1 | 1977 | 8 | 0.010 |
Why?
|
| Purine Nucleosides | 1 | 1977 | 30 | 0.010 |
Why?
|
| Informed Consent | 1 | 1984 | 1008 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1977 | 1625 | 0.010 |
Why?
|
| Intradermal Tests | 1 | 1977 | 42 | 0.010 |
Why?
|
| Monocytes | 1 | 1987 | 2570 | 0.010 |
Why?
|
| Pyrimethamine | 2 | 1988 | 94 | 0.010 |
Why?
|
| Macaca mulatta | 5 | 1983 | 2329 | 0.010 |
Why?
|
| Hemochromatosis | 1 | 1979 | 174 | 0.010 |
Why?
|
| Twins | 1 | 1999 | 339 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1980 | 458 | 0.010 |
Why?
|
| Isoelectric Focusing | 2 | 1974 | 150 | 0.010 |
Why?
|
| Daunorubicin | 1 | 1977 | 157 | 0.010 |
Why?
|
| Acute Kidney Injury | 2 | 1981 | 1924 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 1986 | 2448 | 0.010 |
Why?
|
| Guanosine | 1 | 1976 | 48 | 0.010 |
Why?
|
| Stomatitis | 1 | 1979 | 271 | 0.010 |
Why?
|
| Public Opinion | 1 | 2001 | 484 | 0.010 |
Why?
|
| Neutropenia | 1 | 2002 | 885 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1978 | 561 | 0.010 |
Why?
|
| Blood Platelets | 5 | 1983 | 2479 | 0.010 |
Why?
|
| Triazines | 1 | 1978 | 311 | 0.010 |
Why?
|
| Life Change Events | 1 | 2002 | 952 | 0.010 |
Why?
|
| Drug Combinations | 3 | 1989 | 2048 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 1977 | 159 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 1979 | 335 | 0.010 |
Why?
|
| Diploidy | 1 | 1976 | 132 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1977 | 659 | 0.010 |
Why?
|
| Spouses | 1 | 1999 | 283 | 0.010 |
Why?
|
| Adolescent Behavior | 1 | 2005 | 1190 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1999 | 1991 | 0.010 |
Why?
|
| Thermodynamics | 1 | 1978 | 595 | 0.010 |
Why?
|
| Respiratory System | 1 | 1979 | 563 | 0.010 |
Why?
|
| Remission Induction | 1 | 2002 | 2397 | 0.010 |
Why?
|
| Splenectomy | 2 | 1975 | 391 | 0.010 |
Why?
|
| Lymphoma, Follicular | 2 | 1995 | 457 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2023 | 80647 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1980 | 1463 | 0.010 |
Why?
|
| Eye Neoplasms | 1 | 1977 | 307 | 0.010 |
Why?
|
| Oxidation-Reduction | 2 | 1980 | 2231 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1993 | 11530 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 1975 | 141 | 0.010 |
Why?
|
| Mycosis Fungoides | 1 | 1977 | 170 | 0.010 |
Why?
|
| Semustine | 1 | 1994 | 11 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 1062 | 0.010 |
Why?
|
| Hepatectomy | 1 | 1979 | 557 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1975 | 340 | 0.010 |
Why?
|
| Skin | 2 | 1979 | 4484 | 0.010 |
Why?
|
| Personality | 1 | 1999 | 554 | 0.010 |
Why?
|
| Cystadenocarcinoma | 1 | 1974 | 54 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 1977 | 317 | 0.010 |
Why?
|
| Uric Acid | 1 | 1981 | 807 | 0.010 |
Why?
|
| Carbenicillin | 1 | 1974 | 12 | 0.010 |
Why?
|
| Cephalothin | 1 | 1974 | 28 | 0.010 |
Why?
|
| BRCA2 Protein | 1 | 2000 | 805 | 0.010 |
Why?
|
| Nausea | 2 | 1978 | 679 | 0.010 |
Why?
|
| Polymyxins | 1 | 1974 | 17 | 0.010 |
Why?
|
| Bacitracin | 1 | 1974 | 24 | 0.010 |
Why?
|
| Culture Media | 1 | 1976 | 897 | 0.010 |
Why?
|
| Psychotherapy | 1 | 2004 | 1647 | 0.010 |
Why?
|
| Rifampin | 1 | 1976 | 339 | 0.010 |
Why?
|
| Temperature | 1 | 1981 | 2226 | 0.010 |
Why?
|
| Hydrolysis | 2 | 1972 | 664 | 0.010 |
Why?
|
| Neomycin | 1 | 1974 | 92 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1995 | 614 | 0.010 |
Why?
|
| Blepharitis | 1 | 1974 | 35 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1974 | 299 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 11076 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1977 | 559 | 0.010 |
Why?
|
| Thoracic Vertebrae | 1 | 1999 | 597 | 0.010 |
Why?
|
| Deamination | 1 | 1973 | 25 | 0.010 |
Why?
|
| Xanthurenates | 2 | 1971 | 6 | 0.010 |
Why?
|
| Estradiol | 1 | 1981 | 1937 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1982 | 2209 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2000 | 1263 | 0.010 |
Why?
|
| Asparaginase | 1 | 1975 | 240 | 0.010 |
Why?
|
| Nucleosides | 1 | 1974 | 131 | 0.010 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 1993 | 23 | 0.010 |
Why?
|
| Abdomen | 1 | 1979 | 1128 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1975 | 523 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 4243 | 0.010 |
Why?
|
| Gentamicins | 1 | 1974 | 243 | 0.010 |
Why?
|
| Vancomycin | 1 | 1976 | 503 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 1973 | 189 | 0.010 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1973 | 88 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 1972 | 104 | 0.010 |
Why?
|
| Kynurenine | 2 | 1971 | 141 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 9420 | 0.010 |
Why?
|
| Resins, Plant | 1 | 1972 | 20 | 0.010 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1972 | 82 | 0.010 |
Why?
|
| Diarrhea | 1 | 1979 | 1318 | 0.010 |
Why?
|
| Clinical Competence | 1 | 1988 | 4793 | 0.010 |
Why?
|
| Menopause | 2 | 1978 | 1646 | 0.010 |
Why?
|
| Vidarabine | 1 | 1994 | 336 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1988 | 3763 | 0.010 |
Why?
|
| Cobalt | 1 | 1972 | 154 | 0.010 |
Why?
|
| Choriocarcinoma | 1 | 1972 | 121 | 0.010 |
Why?
|
| Macrophages | 1 | 1987 | 5767 | 0.010 |
Why?
|
| Carcinoma | 2 | 1991 | 2330 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2002 | 1394 | 0.010 |
Why?
|
| Neutrophils | 2 | 1995 | 3767 | 0.010 |
Why?
|
| Pedigree | 1 | 2000 | 4542 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 1984 | 2373 | 0.010 |
Why?
|
| Adenosine | 1 | 1976 | 808 | 0.010 |
Why?
|
| Folic Acid Deficiency | 1 | 1972 | 117 | 0.010 |
Why?
|
| Nickel | 1 | 1972 | 128 | 0.010 |
Why?
|
| Bone and Bones | 2 | 1979 | 2568 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1972 | 321 | 0.010 |
Why?
|
| Child, Preschool | 5 | 2005 | 42232 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1972 | 621 | 0.010 |
Why?
|
| Diaphragm | 1 | 1973 | 351 | 0.010 |
Why?
|
| Skin Tests | 2 | 1971 | 637 | 0.010 |
Why?
|
| Blood | 1 | 1974 | 596 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1976 | 1626 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1989 | 11904 | 0.010 |
Why?
|
| Zinc | 2 | 1972 | 690 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1978 | 1265 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1991 | 813 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1991 | 246 | 0.010 |
Why?
|
| Cytosol | 2 | 1988 | 888 | 0.010 |
Why?
|
| Nitrogen Mustard Compounds | 3 | 1975 | 44 | 0.010 |
Why?
|
| Reticulocytes | 1 | 1991 | 289 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1972 | 387 | 0.010 |
Why?
|
| Spinal Cord Diseases | 1 | 1973 | 292 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1974 | 517 | 0.010 |
Why?
|
| Levulinic Acids | 1 | 1970 | 16 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1978 | 954 | 0.010 |
Why?
|
| Radiology | 1 | 1984 | 2113 | 0.010 |
Why?
|
| Duodenum | 1 | 1973 | 490 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1979 | 1297 | 0.010 |
Why?
|
| Vomiting | 1 | 1973 | 651 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 3 | 1977 | 22174 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2003 | 2492 | 0.010 |
Why?
|
| Cesarean Section | 1 | 1999 | 1398 | 0.010 |
Why?
|
| Pyridoxine | 1 | 1970 | 108 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1970 | 309 | 0.010 |
Why?
|
| Hematopoiesis | 2 | 1976 | 2050 | 0.010 |
Why?
|
| Copper | 1 | 1972 | 369 | 0.010 |
Why?
|
| Enzyme Stability | 1 | 1990 | 219 | 0.010 |
Why?
|
| Mercury | 1 | 1972 | 290 | 0.010 |
Why?
|
| Streptococcus | 1 | 1970 | 198 | 0.010 |
Why?
|
| Manganese | 1 | 1972 | 393 | 0.010 |
Why?
|
| Hypotension | 1 | 1995 | 879 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1999 | 1879 | 0.010 |
Why?
|
| Medical Indigency | 1 | 1988 | 63 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1978 | 12973 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2002 | 3029 | 0.010 |
Why?
|
| Pregnancy | 2 | 2003 | 29890 | 0.000 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1972 | 333 | 0.000 |
Why?
|
| Gene Library | 1 | 1991 | 1059 | 0.000 |
Why?
|
| Myotonic Dystrophy | 1 | 1969 | 78 | 0.000 |
Why?
|
| Cardiomyopathies | 1 | 2000 | 1964 | 0.000 |
Why?
|
| Emotions | 1 | 2000 | 2739 | 0.000 |
Why?
|
| Family | 1 | 1999 | 3195 | 0.000 |
Why?
|
| Pentamidine | 1 | 1987 | 44 | 0.000 |
Why?
|
| Methylene Blue | 1 | 1987 | 155 | 0.000 |
Why?
|
| Amides | 1 | 1970 | 449 | 0.000 |
Why?
|
| Amino Acids | 2 | 1971 | 1718 | 0.000 |
Why?
|
| Injections, Subcutaneous | 1 | 1988 | 681 | 0.000 |
Why?
|
| Nerve Tissue Proteins | 1 | 1980 | 4415 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1970 | 864 | 0.000 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1999 | 2151 | 0.000 |
Why?
|
| Cohort Studies | 2 | 2004 | 41495 | 0.000 |
Why?
|
| Stroke Volume | 1 | 2000 | 5496 | 0.000 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1974 | 1277 | 0.000 |
Why?
|
| DNA Replication | 1 | 1973 | 1418 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1975 | 2910 | 0.000 |
Why?
|
| Cost Control | 1 | 1988 | 628 | 0.000 |
Why?
|
| HLA-DR Antigens | 1 | 1988 | 602 | 0.000 |
Why?
|
| Substance-Related Disorders | 1 | 2003 | 4420 | 0.000 |
Why?
|
| Phosphoribosyl Pyrophosphate | 1 | 1985 | 5 | 0.000 |
Why?
|
| Antigens | 1 | 1971 | 1443 | 0.000 |
Why?
|
| Carbon Dioxide | 1 | 1970 | 1147 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 6075 | 0.000 |
Why?
|
| Epitopes | 1 | 1991 | 2503 | 0.000 |
Why?
|
| Lung Diseases | 1 | 1975 | 1909 | 0.000 |
Why?
|
| Follow-Up Studies | 4 | 2000 | 39106 | 0.000 |
Why?
|
| Guanosine Triphosphate | 1 | 1985 | 316 | 0.000 |
Why?
|
| Calcium | 1 | 1977 | 5722 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 3810 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1975 | 2091 | 0.000 |
Why?
|
| Mathematics | 1 | 1985 | 707 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1982 | 5368 | 0.000 |
Why?
|
| Heart | 1 | 1977 | 4404 | 0.000 |
Why?
|
| Social Justice | 1 | 1988 | 478 | 0.000 |
Why?
|
| Anemia | 2 | 1971 | 1509 | 0.000 |
Why?
|
| Costs and Cost Analysis | 1 | 1988 | 1668 | 0.000 |
Why?
|
| Nucleotides | 1 | 1985 | 454 | 0.000 |
Why?
|
| Esters | 2 | 1973 | 211 | 0.000 |
Why?
|
| Phenotype | 1 | 1999 | 16592 | 0.000 |
Why?
|
| Weight Loss | 1 | 1972 | 2684 | 0.000 |
Why?
|
| Homeostasis | 1 | 1991 | 3323 | 0.000 |
Why?
|
| Burkitt Lymphoma | 1 | 1982 | 335 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2000 | 12130 | 0.000 |
Why?
|
| Radiotherapy Dosage | 2 | 1977 | 2898 | 0.000 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1979 | 221 | 0.000 |
Why?
|
| Lung | 1 | 1977 | 10002 | 0.000 |
Why?
|
| Propionibacterium acnes | 1 | 1978 | 65 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1999 | 26202 | 0.000 |
Why?
|
| Hepatic Artery | 1 | 1979 | 232 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1991 | 7593 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1977 | 137 | 0.000 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 1 | 1976 | 45 | 0.000 |
Why?
|
| BCG Vaccine | 1 | 1979 | 369 | 0.000 |
Why?
|
| Intestinal Perforation | 1 | 1978 | 249 | 0.000 |
Why?
|
| Splenic Neoplasms | 1 | 1976 | 94 | 0.000 |
Why?
|
| Nervous System | 1 | 1978 | 545 | 0.000 |
Why?
|
| Arm | 1 | 1978 | 589 | 0.000 |
Why?
|
| Agranulocytosis | 1 | 1975 | 97 | 0.000 |
Why?
|
| Maryland | 1 | 1975 | 277 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1976 | 698 | 0.000 |
Why?
|
| Castration | 1 | 1974 | 151 | 0.000 |
Why?
|
| Body Surface Area | 1 | 1974 | 197 | 0.000 |
Why?
|
| Blood Specimen Collection | 1 | 1975 | 238 | 0.000 |
Why?
|
| Diet | 1 | 1971 | 8075 | 0.000 |
Why?
|
| Chlorine | 1 | 1973 | 57 | 0.000 |
Why?
|
| Spectrophotometry, Infrared | 1 | 1973 | 117 | 0.000 |
Why?
|
| Leg | 1 | 1978 | 1088 | 0.000 |
Why?
|
| Hematopoietic System | 1 | 1973 | 110 | 0.000 |
Why?
|
| Bromine | 1 | 1972 | 23 | 0.000 |
Why?
|
| Electrophoresis, Disc | 1 | 1971 | 66 | 0.000 |
Why?
|
| Chromatography, Paper | 1 | 1971 | 76 | 0.000 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1971 | 81 | 0.000 |
Why?
|
| Ammonium Sulfate | 1 | 1971 | 30 | 0.000 |
Why?
|
| Chlorambucil | 1 | 1972 | 42 | 0.000 |
Why?
|
| Histoplasmin | 1 | 1971 | 2 | 0.000 |
Why?
|
| Adrenalectomy | 1 | 1974 | 346 | 0.000 |
Why?
|
| Tuberculin | 1 | 1971 | 64 | 0.000 |
Why?
|
| Coccidioides | 1 | 1971 | 18 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1975 | 505 | 0.000 |
Why?
|
| Mannitol | 1 | 1972 | 180 | 0.000 |
Why?
|
| Primary Myelofibrosis | 1 | 1973 | 209 | 0.000 |
Why?
|
| Phenylbutyrates | 1 | 1971 | 72 | 0.000 |
Why?
|
| Busulfan | 1 | 1972 | 258 | 0.000 |
Why?
|
| Deficiency Diseases | 1 | 1971 | 74 | 0.000 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1978 | 1116 | 0.000 |
Why?
|
| Hydroxyurea | 1 | 1972 | 284 | 0.000 |
Why?
|
| Medicare | 1 | 1988 | 6770 | 0.000 |
Why?
|
| Candida | 1 | 1971 | 172 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1988 | 10194 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1977 | 1189 | 0.000 |
Why?
|
| Sex Factors | 2 | 1976 | 10554 | 0.000 |
Why?
|
| Alopecia | 1 | 1974 | 412 | 0.000 |
Why?
|
| Lymphopenia | 1 | 1971 | 281 | 0.000 |
Why?
|
| Radiation Dosage | 1 | 1977 | 1958 | 0.000 |
Why?
|
| Skin Diseases | 1 | 1975 | 1094 | 0.000 |
Why?
|
| Mastectomy | 1 | 1974 | 1822 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1973 | 2612 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1972 | 5485 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 1976 | 5821 | 0.000 |
Why?
|
| Infant | 1 | 1975 | 36193 | 0.000 |
Why?
|